GAMMA Investing LLC Has $397,000 Position in Kenvue Inc. (NYSE:KVUE)

GAMMA Investing LLC grew its position in shares of Kenvue Inc. (NYSE:KVUE) by 17.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,609 shares of the company’s stock after buying an additional 2,719 shares during the quarter. GAMMA Investing LLC’s holdings in Kenvue were worth $397,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Riverview Trust Co bought a new stake in shares of Kenvue during the third quarter worth approximately $30,000. Ashton Thomas Securities LLC acquired a new position in shares of Kenvue in the 3rd quarter valued at $35,000. Versant Capital Management Inc lifted its stake in shares of Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after purchasing an additional 1,441 shares during the period. Studio Investment Management LLC boosted its position in shares of Kenvue by 52.1% in the 2nd quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock worth $45,000 after purchasing an additional 845 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators grew its stake in shares of Kenvue by 49.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after purchasing an additional 651 shares during the period. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

KVUE has been the topic of several analyst reports. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and increased their target price for the company from $21.00 to $26.00 in a research note on Monday. JPMorgan Chase & Co. increased their price target on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and decreased their price objective for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Barclays upgraded shares of Kenvue to a “hold” rating in a report on Thursday, December 12th. Finally, Bank of America boosted their price target on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $23.09.

Kenvue Price Performance

Shares of NYSE KVUE opened at $21.08 on Tuesday. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The stock has a market capitalization of $40.42 billion, a price-to-earnings ratio of 38.33, a PEG ratio of 2.02 and a beta of 1.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The business has a 50-day moving average of $22.81 and a 200-day moving average of $21.53.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The firm had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. During the same period last year, the company earned $0.31 earnings per share. The business’s revenue was down .4% compared to the same quarter last year. As a group, sell-side analysts predict that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were given a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a yield of 3.89%. The ex-dividend date of this dividend was Wednesday, November 13th. Kenvue’s dividend payout ratio (DPR) is currently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.